Key HIV Studies Influencing My Practice Following CROI 2022—Audio Recap
Listen to expert insights from Daniel R. Kuritzkes, MD, and David A. Wohl, MD, on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.
Decera Clinical Education Infectious Disease Podcast · Daniel R. Kuritzkes MD, David A. Wohl MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:
- Prevention strategies
- LA therapies
- Second-line therapies
- The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–based ART for second-line therapy
- The NADIA study comparing dolutegravir with darunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapy
- Comorbidities and cure
- ACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIV
- IMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplant
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases Clinical Trials Unit
University of North Carolina at Chapel Hill
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Follow along with an expanded slideset at:
https://bit.ly/3CItz0Z
Link to full program:
https://bit.ly/3tSpdAx
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.